OncoCyte Gelecekteki Büyüme

Future kriter kontrolleri 2/6

OncoCyte kazanç ve gelirinin sırasıyla yıllık 29.6% ve 106.1% oranında artması tahmin edilirken, EPS'nin yıllık 44.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

29.6%

Kazanç büyüme oranı

44.3%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.4%
Gelir büyüme oranı	106.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	18 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oct 28

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Aug 30

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:OCX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	6	-21	N/A	N/A	2
12/31/2025	1	-24	N/A	N/A	2
12/31/2024	1	-34	N/A	N/A	2
9/30/2024	1	-44	-20	-20	N/A
6/30/2024	1	-37	-18	-18	N/A
3/31/2024	1	-40	-19	-19	N/A
12/31/2023	2	-26	-24	-23	N/A
9/30/2023	1	-22	-29	-29	N/A
6/30/2023	1	-17	-38	-36	N/A
3/31/2023	1	-11	-43	-41	N/A
12/31/2022	1	-19	-50	-46	N/A
9/30/2022	-1	-22	-47	-43	N/A
6/30/2022	0	-34	-46	-43	N/A
3/31/2022	1	-43	-42	-39	N/A
12/31/2021	2	-44	-38	-36	N/A
9/30/2021	5	-35	-37	-35	N/A
6/30/2021	4	-28	-32	-30	N/A
3/31/2021	2	-26	-31	-29	N/A
12/31/2020	1	-30	-27	-26	N/A
9/30/2020	1	-32	-27	-25	N/A
6/30/2020	0	-30	-25	-24	N/A
3/31/2020	0	-26	-21	-20	N/A
12/31/2019	N/A	-22	-21	-20	N/A
9/30/2019	N/A	-19	-17	-17	N/A
6/30/2019	N/A	-17	-15	-14	N/A
3/31/2019	N/A	-16	-16	-16	N/A
12/31/2018	N/A	-16	-12	-12	N/A
9/30/2018	N/A	-15	-13	-13	N/A
6/30/2018	N/A	-19	N/A	-14	N/A
3/31/2018	N/A	-18	N/A	-13	N/A
12/31/2017	N/A	-19	N/A	-13	N/A
9/30/2017	N/A	-19	N/A	-13	N/A
6/30/2017	N/A	-14	N/A	-10	N/A
3/31/2017	N/A	-13	N/A	-9	N/A
12/31/2016	N/A	-11	N/A	-8	N/A
9/30/2016	N/A	-12	N/A	-7	N/A
6/30/2016	N/A	-11	N/A	-7	N/A
3/31/2016	N/A	-10	N/A	-6	N/A
12/31/2015	N/A	-9	N/A	-4	N/A
9/30/2015	N/A	-7	N/A	-3	N/A
6/30/2015	N/A	-5	N/A	-2	N/A
3/31/2015	N/A	-5	N/A	-1	N/A
12/31/2014	N/A	-5	N/A	-1	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OCX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: OCX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: OCX önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: OCX şirketinin gelirinin (yıllık 106.1% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: OCX şirketinin gelirinin (yıllık 106.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OCX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

OncoCyte Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus forecasts updated

Price target decreased to US$2.13

Consensus forecasts updated

Price target decreased to US$3.61

Price target decreased to US$5.02

Consensus revenue estimates fall by 28%

Recent updates

OncoCyte Corporation to Report Q3, 2024 Results on Nov 12, 2024

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $0.316184 million.

OncoCyte Corporation has filed a Follow-on Equity Offering in the amount of $7.5 million.

OncoCyte Corporation to Report Q2, 2024 Results on Aug 08, 2024

Oncocyte Announces Notice of Prior Non-Compliance and Subsequent Compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)

OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial

Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results

OncoCyte Corporation to Report Q1, 2024 Results on May 15, 2024

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

OncoCyte Corporation announced that it has received $15.8 million in funding

Broadwood Capital, Inc. Engages with OncoCyte Corporation

OncoCyte Corporation announced that it expects to receive $15.8 million in funding

OncoCyte Corporation announced delayed annual 10-K filing

Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023

Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage

Oncocyte Corporation Announces Executive Changes

OncoCyte Regains Compliance with Nasdaq Listing Requirements

OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023

Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients

Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

OncoCyte Corporation Announces Reduction of Workforce

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

Consensus forecasts updated

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$2.13

OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Independent Chairman recently bought US$144k worth of stock

OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OncoCyte Corporation Appoints Anish John as Chief Financial Officer

OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors

OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022

OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer

OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index

OncoCyte Corporation, Annual General Meeting, Jul 15, 2022

Consensus forecasts updated

Price target decreased to US$3.61

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test

Revisiting OncoCyte Corp.

High number of new directors

Price target decreased to US$5.02

Broadwood Capital Engages in Discussions with OncoCyte Corporation

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million.

Consensus revenue estimates fall by 28%

Full year 2021 earnings: EPS exceeds analyst expectations

OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022

Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?

OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Price target decreased to US$7.80

Price target decreased to US$8.00

Oncocyte Corporation Announces Results from DetermaIO™ Test

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020)